NCT07126236 - Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 4, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

Large B Cell Lymphoma

Interventions

DRUG

Epcoritamab

Patients will receive 12 cycles of Epcoritamab monotherapy.

DRUG

Epcoritamab, tafasitamab and lenalidomide

Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide.

Trial Locations (15)

10003

NOT_YET_RECRUITING

Hospital San Pedro de Alcántara, Cáceres

28007

RECRUITING

Hospital General Universitario Gregorio Marañón, Madrid

28031

NOT_YET_RECRUITING

Hospital Universitario Infanta Leonor, Madrid

28040

NOT_YET_RECRUITING

Hospital Universitario Fundación Jiménez Díaz, Madrid

29603

NOT_YET_RECRUITING

Hospital Universitario Costa del Sol, Marbella

30120

NOT_YET_RECRUITING

Hospital Virgen de la Arrixaca, El Palmar

33011

NOT_YET_RECRUITING

Hospital Universitario Central de Asturias, Oviedo

38320

NOT_YET_RECRUITING

Hospital Universitario de Canarias, San Cristóbal de La Laguna

46017

NOT_YET_RECRUITING

Hospital Universitario Dr. Peset, Valencia

46024

NOT_YET_RECRUITING

Hospital Universitario y Politécnico La Fe, Valencia

48013

NOT_YET_RECRUITING

Hospital Universitario de Basurto, Bilbao

50009

NOT_YET_RECRUITING

Hospital Universitario Miguel Servet, Zaragoza

09006

NOT_YET_RECRUITING

Hospital Universitario de Burgos, Burgos

08916

NOT_YET_RECRUITING

ICO Badalona, Badalona

08035

NOT_YET_RECRUITING

Hospital Universitari Vall d'Hebrón, Barcelona